Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has established 'Rare Disease Research Unit,' a new research unit to focus on the discovery of novel, life-saving medicines for rare diseases affecting less than 200,000 patients.
Subscribe to our email newsletter
Pfizer’s ‘Rare Disease Research Unit’ is expected to pursue treatments across all therapeutic areas and modalities and will serve as the focal point for the company’s existing research on rare diseases.
Further, Pfizer plans to work closely with patient advocacy groups as it develops and advances the unit’s research strategy.
The ‘Rare Diseases Research Unit’ will be lead by Edward Mascioli. He was the founder and CEO of Dapis Capital, a private equity firm focused on healthcare and the life sciences. He will be based in Cambridge, Mass and will report into Gutierrez-Ramos.
Jose Carlos Gutierrez-Ramos, senior vice president of BioTherapeutics Research and Development, said: “We are very excited about our new Rare Diseases Research Unit. We are coupling Pfizer’s existing experience in rare diseases, such as hemophilia, with our advanced protein technologies, resources and scientific team to focus on becoming a driving force in rare disease research.
“Pfizer has a long history in discovering, developing and commercialising medicines that treat rare diseases and we are hopeful that this research unit will lead to additional new medicines for patients suffering from devastating illnesses for which there is no cure.”